Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to -$3.8 million.

  • Amphastar Pharmaceuticals' Non Operating Income rose 5934.86% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.3 million, marking a year-over-year increase of 3222.34%. This contributed to the annual value of -$15.7 million for FY2024, which is 3891.45% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Non Operating Income stood at -$3.8 million for Q3 2025, which was up 5934.86% from -$2.8 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Non Operating Income registered a high of $13.3 million during Q3 2021, and its lowest value of -$12.6 million during Q4 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Non Operating Income value was -$1.7 million (recorded in 2022), while the average stood at -$1.3 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Non Operating Income tumbled by 133053.8% in 2023 and then skyrocketed by 161820.51% in 2024.
  • Amphastar Pharmaceuticals' Non Operating Income (Quarter) stood at $2.9 million in 2021, then rose by 15.58% to $3.4 million in 2022, then plummeted by 474.26% to -$12.6 million in 2023, then skyrocketed by 90.65% to -$1.2 million in 2024, then tumbled by 222.08% to -$3.8 million in 2025.
  • Its last three reported values are -$3.8 million in Q3 2025, -$2.8 million for Q2 2025, and -$6.4 million during Q1 2025.